IFA
12.9.2019 11:59:07 CEST | Business Wire | Press release
IFA Berlin has turned out to be another huge success story with nearly 2,000 exhibitors, 245,000 visitors, and a new all-time high for international attendance, with more than 50 percent of trade visitors coming from abroad. Three big technology trends dominated IFA across both consumer electronics and home appliances: voice, artificial intelligence and connectivity, especially given the rapid roll-out of high-speed, high bandwidth 5G mobile networks.
Two IFA Keynotes – by Huawei CEO Richard Yu and Qualcomm President Cristiano Amon - focused on how 5G-connectivity can push the power of artificial intelligence to the very edge of computing – in the devices, into vehicles and into industrial applications.
Anthony Wood , the CEO of Roku – which powers one third of all set-top boxes in the United States – used his keynote to outline his vision of how online streaming will dominate the TV experience, and announced his company’s expansion to the UK, with plans to move to other European countries as well. Hakan Bulgurlu , the CEO of Arçelik, dedicated his keynote to demanding industry action against climate change and plastic waste.
IFA’s innovation hub – IFA NEXT – also set new records with more start-ups and innovation leaders than ever spread across two halls, alongside research institutes from countries like Germany, Japan and Korea. This year, IFA NEXT hosted Japan as its first Global Innovation Partner country; the Japan pavilion was showcasing the newest ideas and innovations for how machines and humans can interact.
Keita Nishiyama , Director General of Commerce and Information Policy - Bureau, Ministry of Economy, Trade and Industry says "We hope that Japan’s Interface with Consideration and Sensibility has inspired IFA visitors to embrace the future and continue on the path of innovation. As the first partner country of IFA NEXT - we look forward to staying in touch with you. Please follow us as Ninja does!”
Once again, IFA Berlin lived up to its reputation as the world’s most important trade show for consumer electronics and home appliance.
"As an important driving force for trade and industry and the world's most important platform for consumer electronics and home appliances, IFA 2019 met the high expectations. With its large number of innovations, it has a positive influence on the mood in the international markets. With an unexpectedly stable high order volume in regard to the current market situation, the foundation was laid for a successful year-end business," explains Hans-Joachim Kamp , Chairman of the Supervisory Board of IFA organizer gfu Consumer & Home Electronics.
"We are satisfied with the results of IFA 2019. Accordingly, the household appliance industry is optimistic about the future. This year too, IFA has strengthened its position as the world's significant trade show for home appliances and made a positive contribution to the market development," states Dr. Reinhard Zinkann , Chairman of the ZVEI.
The CEO of Messe Berlin, Dr. Christian Göke says IFA had once again shown the "power of co-innovation, where inventors in different sectors and industries inspire each other." He warned that trade wars, trade barriers and political barriers would harm consumers not just by making products more expensive, but by slowing down innovation itself. Picking up a theme developed in one of IFA’s most famous keynotes, by Albert Einstein in 1930, Dr. Göke said that in today’s day and age Einstein would probably "call on the best and the brightest minds in the world, whoever they are, and wherever they live, whichever country they call their home, to pool their knowledge and co-innovate to create a better world."
IFA Executive Director Jens Heithecker was hugely impressed by the level of innovation: "As the number of exhibitors has grown, so did the quality and quantity of innovations as well as the number of product premieres that were shown here in Berlin for the first time."
Global media attendance has gone up yet again; the journalists coming to Berlin work for media organisations covering 160 countries around the world. This shows how important IFA is in the calendar for technology and lifestyle journalists. This year, IFA attracted some 2.800 international journalists from around the world.
Among the broadcasters reporting from IFA Berlin were Al Jazeera from the Arab Emirates, NDTV from India, Nine Network from Australia, the BBC from the United Kingdom, IBA International from Israel, TEKNAVI from Finland, CNBC from the USA, CGTN / CCTV, Global Times as well as the Phoenix Group from China. From France teams from Eurosport, 01net TV, LCI, BFM TV, OUATCH.tv, France 24 and ES 1 reported on the latest IFA news. News agencies such as AP and Reuters were represented, alongside public broadcasters working through the EBU and private broadcasters cooperating through ENEX.
SHIFT – Future of Mobility
SHIFT, the two-day convention on how new technologies are shaping the Future of Mobility, has grown strongly compared to the previous year; among the speakers were top executives from industry giants such as AXA insurance, BMW, Daimler/Smart, Ford Fujitsu and Volkswagen, start-ups like 2Getthere, Iomob, LISNR, Trafi, Vive La Car, what3words and Wundermobility, and mobility pioneers like Zipcar Founder Robin Chase, the former CTO of Barcelona Francesca Bria, former Tata Motors CEO Venkat Sumantran, and a very unusual automotive consultant, Jay Ward the creative director of the Cars Franchise at Pixar Animation Studios.
IFA Global Markets
IFA Global Markets exclusively accessible to trade visitors, suppliers, manufacturers and OEMs / ODMs established itself as a significant part of IFA.
Dirk Koslowski
, IFA Director, states: "IFA Global Markets has been growing continuously for four years now. It is thus the leading platform in Europe for the supplier industry and has firmly established its position as the largest sourcing show in Europe."
Covering 20,000 square meters, the B2B marketplace IFA Global Markets was once again fully booked.
IFA Global Events – Save the Dates
CE China 2019
19 - 21 September, Guangzhou, China
CE Week 2020
10 - 11 June, New York, USA
IFA Global Press Conference 2020
2 - 5 April, Cyprus
IFA 2020
4 - 9 September
2 - 3 September, IFA Media Days
2 September, IFA Opening Press Conference, 1 p.m.
6 - 9 September IFA Global Markets
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005397/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
